Isavuconazonium
- Generic Name
- Isavuconazonium
- Brand Names
- Cresemba
- Drug Type
- Small Molecule
- Chemical Formula
- C35H35F2N8O5S
- CAS Number
- 742049-41-8
- Unique Ingredient Identifier
- VH2L779W8Q
- Background
Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA for the treatment of invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in wate...
- Indication
Indicated in the treatment of invasive aspergillosis and invasive mucormycosis.
- Associated Conditions
- Disseminated mucormycosis, Invasive Aspergillosis
- Associated Therapies
- -
Study on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
- Conditions
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Shanghai Children's Medical Center
- Target Recruit Count
- 200
- Registration Number
- NCT06440915
- Locations
- 🇨🇳
Shanghai Children's Medical Center, Shanghai, China
Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 70
- Registration Number
- NCT05630976
- Locations
- 🇨🇳
Qilu Hospital of Shandong University, Jinan, Shandong, China
🇨🇳Liaocheng people's Hospital, Liaocheng, Shandong, China
🇨🇳Jiading Central Hospital, Shanghai, China
A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Acerta Pharma BV
- Target Recruit Count
- 30
- Registration Number
- NCT05140096
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis
- Conditions
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 307
- Registration Number
- NCT04550936
- Locations
- 🇫🇷
Hôpital Huriez CHU de Lille, Lille, France
🇫🇷Institut de Cancérologie, Strasbourg, France
🇫🇷CHU de Limoges, Limoges, France
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03964090
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 99
- Registration Number
- NCT03149055
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT03019939
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 93
- Registration Number
- NCT02203526
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128321
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2014-05-01
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02128893
- Locations
- 🇺🇸
Parexel Early Phase Clinical Unit, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.